A team of independent advisers to the Centers for Disease Control and Prevention has a science-based outline for deploying a vaccine when it's ready. The goal is to stop deaths and viral spread fast.
NPR's Mary Louise Kelly talks with Jose Romero, chair of the Centers for Disease Control and Prevention's immunization committee, about the committee's recommendations for coronavirus vaccination.
In talk of the impact Amy Coney Barrett could have on abortion rights, many people overlook related cases that might be in play, including the right to birth control that the court recognized in 1965.
Drug industry veteran Moncef Slaoui is a key figure in Operation Warp Speed's push to develop COVID-19 coronavirus vaccines. His employment terms raised concerns about potential conflicts of interest.
In advance of a COVID-19 vaccine being available, a group of independent medical advisers to the Centers for Disease Control and Prevention weighed Friday who should get the vaccine first and how.
The federal government plans to distribute 300,000 doses of the drug at no cost, but that doesn't mean treatment will be free. Intravenous infusion charges can run more than $1,000.
The trial studied the efficacy of bamlanivimab in combination with the antiviral remdesivir on hospitalized COVID-19 patients. Researchers concluded the antibody treatment was "unlikely to help."
Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability.
A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines.
The U.S. Food and Drug Administration has approved the first drug to treat COVID-19. Remdesivir is an antiviral medicine given through an IV for patients needing hospitalization.
Experimental medicines have the potential to help people with COVID-19 avoid hospitalization. The scarce supply of the treatments would have to be rationed, if regulators OK their use.
More hospitalized patients are surviving than early in the pandemic. Improved treatments make a big difference, but so does flattening the curve to keep hospitals from overfilling, researchers say.
The average wait time for results has dropped to about three days, but that is still too slow to keep infected people from unknowingly spreading the virus, researchers report.
